23andMe Investor Presentation Deck
Inhibition of CD200R1 has the potential to address
resistance to anti-PD1 therapies
Fold Change Relative to Control
Blocking the CD200R1 pathway enhanced IFNy production from SEB-stimulated
PBMCs compared to isotype control and anti-PD1 in the majority of samples tested
*
*
Endometrial 1
Endometrial 2
*
Ovarian 1
Interferon-y
*
Lung
*
Melanoma
Pancreatic
Endometrial 3
PBMCs from each respective patient were incubated with 100 nM of 23ME-00610, anti-PD-1, or isotype control. Cells were stimulated with SEB.
IFNY levels were determined by enzyme-linked immunosorbent assay. Mean biologic triplicates were normalized to isotype control. *P <0.05.
23ME '610
Isotype Control
anti-PD1
Prostate
Colorectal
Copyright © 2023 23andMe, Inc.
PBMC, peripheral blood
mononuclear cell; PD-1,
programmed death-1; SEB,
staphylococcal enterotoxin B.
23andMe
44View entire presentation